retatrutide clinical data VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide clinical data FDA Approval

Obesity is linked to several comorbidities, such as diabetes and heart failure

Helmstadter J, Keppeler K, Kuster L, Munzel T, Daiber A, Steven S

Injectables currently have stronger trial data and more predictable effects

And, further, for patients with type 2 diabetes (T2DM) taking a GLP-1, the risks are reduced by about 60% and 50%, respectively

The large-scale SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% 13

It helps: Stimulate insulin release Lower blood sugar levels Slow down digestion Increase feelings of fullness In short, GLP-1 is a major player in metabolic health and weight regulation